GIP and type 2 diabetes mellitus: While the effects of exogenous GIP at physiological or pharmacological doses on fasting and postprandial lipids/lipoproteins in type 2 diabetes have not been explicitly published, Stensen et al did not find any changes in basal or postprandial concentrations of NEFAs and glycerol, triacylglycerol, and HDL-, VLDL- and LDL-cholesterol when administering a GIP receptor antagonist (GIP [3–30] NH2) in individuals with type 2 diabetes during a (liquid) meal test, thus ruling out acute effects of endogenously secreted GIP [49].